Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Gain Therapeutics (NASDAQ:GANX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
Earnings and Valuation
This table compares Creative Medical Technology and Gain Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $10,000.00 | 678.77 | -$5.99 million | ($2.07) | -0.50 |
| Gain Therapeutics | $50,000.00 | 1,553.58 | -$20.16 million | ($0.50) | -3.56 |
Profitability
This table compares Creative Medical Technology and Gain Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
Institutional & Insider Ownership
1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Creative Medical Technology has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Creative Medical Technology and Gain Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 321.35%. Given Gain Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Creative Medical Technology.
Summary
Gain Therapeutics beats Creative Medical Technology on 8 of the 13 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
